Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Many polymorphisms in genes, such as ELAC2 (locus HPC2), RNase L (locus hereditary prostate cancer 1 gene [HPC1]), and MSR1 have been recognized as important genetic factors that confer an increased risk of developing prostate cancer in many populations.
|
23141781 |
2013 |
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Polymorphisms in the elaC homolog-2 (ELAC2)/HPC2 gene have been hypothesized to alter the risk of prostate cancer.
|
20231859 |
2010 |
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The HPC2/ELAC2 217L allele was significantly associated with risk of prostate cancer when taking all cases into account (OR = 1.6; 1.0-2.6; P = 0.03).
|
18767027 |
2008 |
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
HPC2/ELAC2 polymorphism associated with Japanese sporadic prostate cancer.
|
15368467 |
2004 |
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Early linkage results have provided targeted candidate regions for prostate cancer susceptibility loci, including HPC1 on chromosome 1q23-25, PCAP on chromosome 1q42-43, CAPB on chromosome 1p36, linkage to chromosome 8p22-23, HPC2 on chromosome 17p, HPC20 on chromosome 20q13, and HPCX on chromosome Xq27-28.
|
14749351 |
2004 |
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The present study suggested that the common variants in the HPC2/ELAC2 gene play a limited role in the risk of prostate cancer in the Japanese population.
|
12552947 |
2003 |
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To determine the contribution of two HPC2/ELAC2 missense variants (Ser217Leu and Ala541Thr) to the risk of developing prostate cancer, we conducted a population-based case-control study of middle-aged men (40-64 years).
|
14504198 |
2003 |
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The ELAC2 gene has been proposed to be a prostate cancer susceptibility gene and is being referred to as HPC2, in part because three case-control studies suggested that two common polymorphisms (Ser217Leu and Ala541Thr) are associated with risk.
|
12783937 |
2003 |
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We tested for possible associations between the two HPC2 gene variants and prostate cancer risk in incident prostate cancer cases (199) and healthy male controls (525) from the Calgary region.
|
14625808 |
2003 |
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
HPC2/ELAC2 polymorphisms and prostate cancer risk: analysis by age of onset of disease.
|
12373607 |
2002 |
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Association of common missense changes in ELAC2 ( HPC2) with prostate cancer in a Japanese case-control series.
|
12522685 |
2002 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conclude that HPC2 genotyping is unlikely to be a useful adjunct to PSA in the prediction of the presence of biopsy-detected prostate cancer in asymptomatic men.
|
11254449 |
2001 |
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The finding of a nonsense mutation in the HPC2/ELAC2 gene confirms its potential role in genetic susceptibility to prostate cancer.
|
11522646 |
2001 |
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
There is, however, little evidence for excess clustering of the T allele within the multiplex families known to be segregating this allele, and there is no evidence for linkage of prostate cancer to the HPC2/ELAC2 region of chromosome 17p11.2 in these families.
|
11431329 |
2001 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Taken together, inactivation of the HPC2/ELAC2 gene via LOH is a relatively uncommon event in prostate cancer.
|
11751379 |
2001 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer.
|
11507049 |
2001 |
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The results of this study lead us to reject the three alternative hypotheses of (1) a highly penetrant, major prostate cancer-susceptibility gene at 17p11, (2) the allelic variants Leu217 or Thr541 of HPC2/ELAC2 as high-penetrance mutations, and (3) the variants Leu217 or Thr541 as low-penetrance, risk-modifying alleles.
|
11254448 |
2001 |
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that common variants at HPC2/ELAC2 are associated with CaP risk in a sample unselected for family history or other factors associated with CaP risk.
|
10986046 |
2000 |